Werewolf Therapeutics Stock Beta
| HOWL Stock | USD 1.20 0.01 0.83% |
Werewolf Therapeutics fundamentals help investors to digest information that contributes to Werewolf Therapeutics' financial success or failures. It also enables traders to predict the movement of Werewolf Stock. The fundamental analysis module provides a way to measure Werewolf Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Werewolf Therapeutics stock.
Werewolf |
Werewolf Therapeutics Company Beta Analysis
Werewolf Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Werewolf Therapeutics Beta | 0.38 |
Most of Werewolf Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Werewolf Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Werewolf Therapeutics has a Beta of 0.378. This is 56.05% lower than that of the Biotechnology sector and 72.81% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Werewolf Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Werewolf Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Werewolf Therapeutics could also be used in its relative valuation, which is a method of valuing Werewolf Therapeutics by comparing valuation metrics of similar companies.Werewolf Therapeutics is currently under evaluation in beta category among its peers.
As returns on the market increase, Werewolf Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Werewolf Therapeutics is expected to be smaller as well.
Werewolf Fundamentals
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (39.04) % | ||||
| Current Valuation | (20.12 M) | ||||
| Shares Outstanding | 44.83 M | ||||
| Shares Owned By Insiders | 6.08 % | ||||
| Shares Owned By Institutions | 63.32 % | ||||
| Number Of Shares Shorted | 1.87 M | ||||
| Price To Earning | 0.84 X | ||||
| Price To Book | 0.73 X | ||||
| Price To Sales | 28.54 X | ||||
| Revenue | 1.89 M | ||||
| Gross Profit | (51.2 M) | ||||
| EBITDA | (64.05 M) | ||||
| Net Income | (70.52 M) | ||||
| Cash And Equivalents | 145.71 M | ||||
| Cash Per Share | 4.93 X | ||||
| Total Debt | 10.99 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.08 X | ||||
| Book Value Per Share | 1.64 X | ||||
| Cash Flow From Operations | (56.19 M) | ||||
| Short Ratio | 7.11 X | ||||
| Earnings Per Share | (1.63) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 10.67 | ||||
| Number Of Employees | 46 | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 53.79 M | ||||
| Total Asset | 126.93 M | ||||
| Retained Earnings | (414.59 M) | ||||
| Working Capital | 97.89 M | ||||
| Net Asset | 126.93 M |
About Werewolf Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Werewolf Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Werewolf Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Werewolf Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Werewolf Therapeutics Piotroski F Score and Werewolf Therapeutics Altman Z Score analysis. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.